Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP & CCO | May 05, 2020 | May 08, 2020 |
| Organon & Co.OGN · Entity 4115 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 05, 2020 · Filed May 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,751 |
Reported balance
After 2020-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 676 · Balance 24,751 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. F2: These shares include the following RSUs granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 604 RSUs which vest in installments of 297 on 4/27/2021 and 307 on 4/27/2022; 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023; and 676 RSUs which vest in two installments of 223 on 5/5/2022 and 5/5/2023, and one installment of 230 on 5/5/2024.. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $236.36 · Expires 2030-05-05 | Direct | 5,668 |
Reported balance
After 2020-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-05 · Grant · Acquired 5,668 · Balance 5,668 F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 270.044 |
Reported balance
Holding disclosure · report date 2020-05-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 270.044 F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.
F2: These shares include the following RSUs granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 604 RSUs which vest in installments of 297 on 4/27/2021 and 307 on 4/27/2022; 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023; and 676 RSUs which vest in two installments of 223 on 5/5/2022 and 5/5/2023, and one installment of 230 on 5/5/2024.. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.
Organon & Co.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 81,141.129 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 17,857.143 · Balance 81,141.129 F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.
F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 20:39 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043247 · wk-form4_1781555983.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.129 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 23,904.382 | $10.04 | $240,000.00 |
DisclosureSEC source: 0001821825-25-000053 · wk-form4_1750109538.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,702.653 Underlying: Common Stock · 23,904.382 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:18 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000080 · wk-form4_1718133477.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.814 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:58 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036793 · doc4.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 23:41 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 5,640 | $35.46 | $199,994.40 |
DisclosureSEC source: 0001104659-22-071142 · tm2218336-10_4seq1.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,638 Underlying: Common Stock · 5,640 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:41 UTC | Organon & Co. OGN · Entity 4115 | GrantPhantom Stock · Derivative | 8,772 | $36.05 | $316,230.60 |
DisclosureSEC source: 0000899243-21-022684 · doc4.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,772 Underlying: Common Stock · 8,772 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document |
| May 05, 2020 Filed May 8, 2020 01:01 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,668 | $0.00 Strike: $236.36 | $0.00 |
DisclosureSEC source: 0001127602-20-015863 · form4.xml · derivative · entry 3 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,668 Underlying: Common Stock · 5,668 shares Expires 2030-05-05 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. Read SEC document |
| May 05, 2020 Filed May 8, 2020 01:01 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 676 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015863 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,751 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 604 RSUs which vest in installments of 297 on 4/27/2021 and 307 on 4/27/2022; 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023; and 676 RSUs which vest in two installments of 223 on 5/5/2022 and 5/5/2023, and one installment of 230 on 5/5/2024.. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2020 Filed May 5, 2020 23:53 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 127 | $230.98 | $29,334.46 |
DisclosureSEC source: 0001127602-20-015548 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,075 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 604 RSUs which vest in installments of 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 01, 2020 Filed May 5, 2020 23:53 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 115 | $239.22 | $27,510.30 |
DisclosureSEC source: 0001127602-20-015548 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,202 Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:00 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 102 | $236.28 | $24,100.56 |
DisclosureSEC source: 0001127602-20-014698 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,317 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 604 RSUs which vest in installments of 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 162 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 22:04 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,481 | $198.76 | $294,363.56 |
DisclosureSEC source: 0001127602-20-011870 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,419 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 179 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:48 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009710 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,848 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 156 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 22:07 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 2,875 | $0.00 Strike: $162.60 | $0.00 |
DisclosureSEC source: 0001127602-19-027930 · form4.xml · derivative · entry 8 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,839 Underlying: Common Stock · 2,875 shares Expires 2027-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 22:07 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,749 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-19-027930 · form4.xml · derivative · entry 7 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,962 Underlying: Common Stock · 5,749 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 22:07 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 4,802 | $208.07 | $999,138.69 |
DisclosureSEC source: 0001127602-19-027930 · form4.xml · nonDerivative · entry 5 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,097 F3 · price: The price reported is an average price. The prices ranged from $207.425 to $208.520 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F4 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F5 · balance_after: These shares include 116 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 22:07 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,875 | $208.07 | $598,193.20 |
DisclosureSEC source: 0001127602-19-027930 · form4.xml · nonDerivative · entry 4 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,899 F2 · price: The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 2,875 stock options expiring May 1, 2027. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 22:07 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 2,875 | $162.60 | $467,475.00 |
DisclosureSEC source: 0001127602-19-027930 · form4.xml · nonDerivative · entry 3 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 22:07 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 5,749 | $208.07 | $1,196,178.33 |
DisclosureSEC source: 0001127602-19-027930 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,899 F1 · price: The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 5,749 stock options expiring May 3, 2026. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 22:07 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,749 | $156.35 | $898,856.15 |
DisclosureSEC source: 0001127602-19-027930 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:02 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 7,876 | $0.00 Strike: $177.31 | $0.00 |
DisclosureSEC source: 0001127602-19-017651 · form4.xml · derivative · entry 4 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,876 Underlying: Common Stock · 7,876 shares Expires 2029-05-03 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:02 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 902 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017651 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,877 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 94 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:02 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 174 | $176.50 | $30,711.00 |
DisclosureSEC source: 0001127602-19-017651 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,975 Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:51 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 164 | $179.32 | $29,409.00 |
DisclosureSEC source: 0001127602-19-017347 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,149 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 122 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 22, 2019 Filed Mar 25, 2019 23:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,515 | $191.89 | $290,713.35 |
DisclosureSEC source: 0001127602-19-013163 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,313 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans:686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 140 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2019 Filed Mar 9, 2019 00:41 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-010657 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,777 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 23:20 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 117 | $192.11 | $22,476.87 |
DisclosureSEC source: 0001127602-19-003511 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,101 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 29, 2018 Filed Dec 4, 2018 01:11 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 1,777 | $0.00 Strike: $54.69 | $0.00 |
DisclosureSEC source: 0001127602-18-035029 · form4.xml · derivative · entry 4 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,777 shares Expires 2021-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2018 Filed Dec 4, 2018 01:11 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,777 | $202.88 | $360,519.89 |
DisclosureSEC source: 0001127602-18-035029 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,313 F1 · price: The price reported is an average price. The prices ranged from $202.19 to $203.59 per share for this cashless exercise of 1,777 stock options expiring April 25, 2021. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 313 RSUs which vest in one installment on 1/30/2019; 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 131 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 29, 2018 Filed Dec 4, 2018 01:11 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 1,777 | $54.69 | $97,184.13 |
DisclosureSEC source: 0001127602-18-035029 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 23:09 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 169 | $169.43 | $28,633.67 |
DisclosureSEC source: 0001127602-18-016538 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,156 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 313 RSUs which vest in one installment on 1/30/2019; 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 90 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:19 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 6,940 | $0.00 Strike: $177.46 | $0.00 |
DisclosureSEC source: 0001127602-18-015842 · form4.xml · derivative · entry 3 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,940 Underlying: Common Stock · 6,940 shares Expires 2028-04-27 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:19 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 901 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015842 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,325 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 313 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 108 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 23:46 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,257 | $176.08 | $221,332.56 |
DisclosureSEC source: 0001127602-18-012860 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,424 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 313 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 108 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:32 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011023 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,640 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 313 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 92 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 01:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 132 | $191.27 | $25,247.64 |
DisclosureSEC source: 0001127602-18-003455 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,113 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 313 RSUs which vest in one installment on 1/30/2019; 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 92 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2018 Filed Feb 2, 2018 01:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 109 | $198.00 | $21,582.00 |
DisclosureSEC source: 0001127602-18-003455 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,245 Read SEC document |
| May 24, 2017 Filed May 24, 2017 23:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,922 | $154.40 | $451,164.11 |
DisclosureSEC source: 0001127602-17-019308 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,292 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 372 RSUs which vest on 1/31/2018; 616 shares which vest in one installment of 303 on 1/30/2018 and one installment of 313 on 1/30/2019; 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 87 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 24, 2017 Filed May 24, 2017 23:35 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-019308 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,214 Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:57 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 8,714 | $0.00 Strike: $162.60 | $0.00 |
DisclosureSEC source: 0001127602-17-016756 · form4.xml · derivative · entry 3 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,714 Underlying: Common Stock · 8,714 shares Expires 2027-05-01 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:57 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 984 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016756 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,560 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 372 RSUs which vest on 1/31/2018; 616 shares which vest in one installment of 303 on 1/30/2018 and one installment of 313 on 1/30/2019; 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; and 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 87 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 22:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,893 | $166.04 | $314,313.72 |
DisclosureSEC source: 0001127602-17-013097 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,576 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 372 RSUs which vest on 1/31/2018; 616 shares which vest in one installment of 303 on 1/30/2018 and one installment of 313 on 1/30/2019; and 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 87 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:14 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 5,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-011102 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,424 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 372 RSUs which vest on 1/31/2018; 616 shares which vest in one installment of 303 on 1/30/2018 and one installment of 313 on 1/30/2019; and 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 74 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 23:53 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 136 | $154.43 | $21,002.48 |
DisclosureSEC source: 0001127602-17-003734 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,421 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 372 RSUs which vest on 1/31/2018; 616 shares which vest in one installment of 303 on 1/30/2018 and one installment of 313 on 1/30/2019; and 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 74 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 00:01 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 113 | $157.16 | $17,759.08 |
DisclosureSEC source: 0001127602-17-003199 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,557 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 732 RSUs which vest in one installment of 360 on 1/31/2017 and one installment of 372 on 1/31/2018; 616 shares which vest in one installment of 303 on 1/30/2018 and one installment of 313 on 1/30/2019; and 1,023 RSUs which vest in one installment of 337 on 5/3/2018, one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 98 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2017 Filed Feb 1, 2017 00:01 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 279 | $157.16 | $43,847.64 |
DisclosureSEC source: 0001127602-17-003199 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,670 Read SEC document |
| October 26, 2016 Filed Oct 27, 2016 00:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,043 | $157.90 | $164,684.49 |
DisclosureSEC source: 0001127602-16-065316 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,924 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 716 RSUs which vest on 1/28/2017; 732 RSUs which vest in one installment of 360 on 1/31/2017 and one installment of 372 on 1/31/2018; and 919 shares that vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 149 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:37 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 8,711 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-16-051294 · form4.xml · derivative · entry 3 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,711 Underlying: Common Stock · 8,711 shares Expires 2026-05-03 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:37 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-051294 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,901 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,843 RSUs which vest on 10/26/2016; 716 RSUs which vest on 1/28/2017; 732 RSUs which vest in one installment of 360 on 1/31/2017 and one installment of 372 on 1/31/2018; 919 shares that vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019; and 1,023 shares that vest in installments of 337 on 5/3/2018, 338 on 5/3/2019 and 348 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 236 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2016 Filed Apr 29, 2016 23:50 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 230 | $162.85 | $37,455.50 |
DisclosureSEC source: 0001127602-16-050339 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,878 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,843 RSUs which vest on 10/26/2016; 716 RSUs which vest on 1/28/2017; 732 RSUs which vest in one installment of 360 on 1/31/2017 and one installment of 372 on 1/31/2018; and 919 shares that vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 236 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.